Organization
Janssen Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Janssen Pharmaceuticals, Inc.
... In August 2017, Cerecor sold full worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. in exchange for initial gross proceeds of $ 25 million, of ...
... March 2015, with the jury finding that Johnson & Johnson and its Janssen Pharmaceuticals subsidiary had failed to properly warn patients and doctors that Risperdal ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ('Janssen') for $ 25 million plus the potential for a $ ...
... Co. Inc.; Teva Pharmaceuticals USA Inc.; Cephalon Inc.; Johnson & Johnson; Janssen Pharmaceuticals Inc.; Ortho-McNeil-Janssen Pharmaceuticals Inc.; Janssen Pharmaceutica Inc.; Endo Health Solutions Inc.; Endo ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ("Janssen") for $25 million plus the potential for a $20 million ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ("Janssen") for $25 million plus the potential for a $20 million ...
... VTE recurrence,' said Paul Burton, MD, PhD, FACC, Vice President, Medical Affairs, Janssen. 'The landmark EINSTEIN program results yet again demonstrate XARELTO is a safe ...
... Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the ...
... at The Phoenician in Scottsdale, AZ. Vanessa Broadhurst, President, Cardiovascular & Metabolism, Janssen Pharmaceuticals and Scott White, President, Immunology, Janssen Pharmaceuticals will represent the Company ...
... of the worldwide license and collaboration arrangement on hepatitis C with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. ...
... Cerveau Technologies, Inc. today announced a research collaboration agreement with Janssen Pharmaceuticals, Inc. for use of [F-18]MK-6240, an investigational imaging agent to be used ...
... Teva Pharmaceutical Industries, Ltd.; Teva Pharmaceuticals USA, Inc.; Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc. n/k/a ...
... Janssen Pharmaceuticals, Inc. today announced the recipients of the inaugural HealtheVoices(TM) Impact Fund grants, ...
... Administration has ordered be removed from the market. Johnson & Johnson s Janssen Pharmaceuticals of Titusville, N.J., makes the fentanyl patch Duragesic. Teva Pharmaceuticals USA, ...
... market by the Food and Drug Administration in June; Johnson & Johnson's Janssen Pharmaceuticals, based in Titusville, N.J., which makes the fentanyl patch Duragesic; Teva ...
... subpoenas and document requests were served Monday to pharmaceutical manufacturers Endo International, Janssen Pharmaceuticals, Teva Pharmaceutical Industries Ltd./Cephalon Inc. and Allergan. The group also served ...
... Wednesday in federal court alleges that Purdue Pharma, Endo Health Solutions and Janssen Pharmaceuticals made false and misleading statements about the benefits and risks of ...
... Oncology Portfolio Marketing & Customer Engagement, Pfizer Cardiology:Robert Burke, Product Director, XARELTO, Janssen Pharmaceuticals Central Nervous System:Samantha Hack, Director, Neurology Marketing, Sunovion Pharmaceuticals, Inc. Dermatology:Rhonda ...
... of the worldwide license and collaboration arrangement on hepatitis C with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. ...
... age. INVOKANA® does not have an indication for CV risk reduction. Janssen Pharmaceuticals, Inc. and its affiliates have rights to canagliflozin through a license agreement ...
... in the Philadelphia region or close to it: Johnson & Johnson s Janssen Pharmaceuticals, based in Titusville, N.J., which marketed Nucynta; Teva Pharmaceuticals, which has ...
... used in executions. Etomidate, an intravenous anesthetic, was invented by scientists from Janssen Pharmaceuticals in the 1960s, according to Greg Panico, a spokesman for the ...
... Portfolio Marketing & Customer Engagement, Oncology, Pfizer Cardiology:Robert Burke, Product Director, XARELTO, Janssen Pharmaceuticals Central Nervous System:Samantha Hack, Director, Neurology Marketing, Sunovion Pharmaceuticals, Inc. Dermatology:Rhonda ...
... -Janssen Pharmaceuticals, Inc. - New XARELTO Data at ESC Congress 2017 Includes Late Breaking ...
... Corrections intends to use etomidate, an anesthetic developed 50 years ago by Janssen Pharmaceuticals. Although the drugmaker sold off the product last year, it has ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤